Henry Gottsch, MD
Urology · Casper, WYNPI 1831209253
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.6% of the total across 218 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations.
Across 218 payments — averaging $20.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dendreon Pharmaceuticals LLC$609
- Astellas Pharma US Inc$580
- Johnson & Johnson$468
- Sumitomo Pharma America, Inc.$382
- Pfizer$338
- Bayer$212
- plus $2K from 29 others
What the payments were for
- Travel & lodging$60%
- Food & beverage$4,13593%
- Education$3247%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dendreon Pharmaceuticals LLC | 35 | $609 |
| Astellas Pharma US Inc | 28 | $580 |
| Johnson & Johnson | 23 | $468 |
| Sumitomo Pharma America, Inc. | 19 | $382 |
| Pfizer | 17 | $338 |
| Bayer | 10 | $212 |
| Boston Scientific | 8 | $199 |
| Merck | 8 | $166 |
| Coloplast | 7 | $158 |
| Myovant Sciences Inc. | 8 | $157 |
| Axonics, Inc. | 5 | $146 |
| AbbVie(2 entities) | 7 | $138 |
| Novartis | 4 | $113 |
| Endo Pharmaceuticals Inc. | 5 | $99 |
| Teleflex LLC | 3 | $77 |
| Procept Biorobotics Corporation | 2 | $62 |
| 180 Medical, Inc. | 3 | $61 |
| Tolmar Pharmaceuticals, Inc. | 3 | $54 |
| Intuitive Surgical | 2 | $45 |
| Rochester Medical Corporation | 2 | $43 |
| Palette Life Sciences, Inc. | 2 | $42 |
| Calyxo, Inc. | 1 | $42 |
| Accord Healthcare, Inc. | 2 | $35 |
| Medtronic | 2 | $34 |
| Ambu Inc. | 2 | $28 |
| Immunitybio, Inc. | 1 | $24 |
| Urogen Pharma, Inc. | 1 | $24 |
| Tolmar, Inc. | 1 | $24 |
| Dornier Medtech America, Inc | 1 | $18 |
| Olympus America Inc. | 1 | $17 |
| Cook Medical LLC | 1 | $16 |
| Amgen | 1 | $15 |
| Angiodynamics, Inc. | 1 | $14 |
| AstraZeneca | 1 | $12 |
| Profound Medical Corp. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROVENGE$138
How this compares
Too few urology providers in Wyomingto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 70 | $1,025,540 |
| OrgovyxRelugolix | 148 | $383,139 |
| MyrbetriqMirabegron | 195 | $114,407 |
| Tamsulosin Hcl | 687 | $14,165 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 58 | $9,458 |
| Mirabegron ErMirabegron | 16 | $6,480 |
| Oxybutynin Chloride ErOxybutynin Chloride | 315 | $5,395 |
| Finasteride | 352 | $4,990 |
| RenacidinCitric Ac/Gluconolact/Mag Carb | 12 | $3,672 |
| Potassium Citrate ErPotassium Citrate | 23 | $3,638 |
| Estradiol | 48 | $3,361 |
| Testosterone Cypionate | 60 | $1,562 |
| Trospium Chloride | 19 | $1,278 |
| Tolterodine Tartrate ErTolterodine Tartrate | 27 | $1,259 |
| Solifenacin Succinate | 34 | $720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $468 | $1,025,54070 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $382 | $383,139148 claims |
| Astellas Pharma US IncMyrbetriq | $580 | $114,407195 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urology providers in Wyomingon file to place this against a meaningful peer group, so we don't.
Other urology in Casper
- Brandon TrojanCasper$4K
- John JonesCasper$2K
- James HadenCasper$26
- John BryantCheyenne$8K
- Cody ChristensenRock Springs$4K
- Ted MorganJackson$3K
- Stephen HolstSheridan$3K
- Attila BarabasGillette$3K
- Harold PierceLaramie$2K
- Wallace CurryRock Springs$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.